Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company pioneering treatments for aggressive central nervous system cancers. This page provides investors and medical stakeholders with timely updates on the company’s groundbreaking therapies, including Berubicin for glioblastoma and TPI 287 for advanced CNS tumors.
Access consolidated updates on clinical trial progress, FDA designations, and strategic partnerships. Our news feed covers critical developments in the company’s pipeline, including Phase II results for Berubicin – the first anthracycline to cross the blood-brain barrier – and preclinical advancements for TPI 287’s microtubule-stabilizing mechanism.
Key coverage areas include regulatory milestones, peer-reviewed research publications, and collaborations with leading institutions like MD Anderson Cancer Center. Bookmark this page for verified updates on CNS Pharmaceuticals’ efforts to address unmet needs in neuro-oncology through innovative science and targeted drug development.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit in Boston, MA, from February 18-20, 2025. Chief Medical Officer Sandra Silberman, MD, PhD, will present on February 20 at 10:45 AM ET, discussing novel formulations of anthracycline and taxane that can cross the Blood-Brain Barrier (BBB).
The company's lead program, Berubicin, has shown efficacy in Phase 1 and completed enrollment with 252 patients in its pivotal study versus Lomustine for GBM treatment. Primary analysis data is expected in the first half of 2025. CNS is also advancing TPI 287, an abeotaxane showing significant activity in Phase 1b studies.
The FDA has granted Fast Track Designation for Berubicin, allowing more frequent agency interactions, and Orphan Drug Designation for treating malignant glioma, potentially providing seven years of marketing exclusivity upon NDA approval.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the BIO CEO & Investor Conference in New York, NY.
The company's CEO, John Climaco, is scheduled to present on Monday, February 10, 2025, at 1:15 PM ET in the Royale Room. The conference runs from February 10-11, 2025.
Management will be available for one-on-one meetings with conference attendees, who can schedule meetings through the BIO CEO attendee portal. Interested parties can find additional conference information at bcic.bio.org.
CNS Pharmaceuticals (NASDAQ:CNSP) announces a Virtual Analyst & Investor Day scheduled for December 11th, 2024, from 11:30 AM to 1:00 PM ET. The event will feature discussions on Glioblastoma Multiforme (GBM), an aggressive brain cancer with only 14-16 months average survival post-diagnosis.
The presentation will include key company executives and renowned medical experts: CEO John Climaco, CMO Sandra Silberman, VP of Clinical Operations Zena Muzyczenko, along with KOLs Michael Weller, Samuel Goldlust, and Erin Dunbar.
The agenda includes an overview of Berubicin and its clinical development program, plus discussion of their second asset, TPI 287. The event will be accessible via webcast on the company's website, with replay available for 90 days.
CNS Pharmaceuticals (NASDAQ:CNSP) presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between treatment arms. Key findings show higher study completion rates in the Berubicin arm (84.7% vs 78.9%) and lower withdrawal rates (11.0% vs 19.7%) compared to Lomustine. Safety profiles were similar between arms, with Berubicin showing slightly higher rates of anemia and neutropenia, while Lomustine had more thrombocytopenia cases. The company expects to report primary analysis data in the first half of 2025.
CNS Pharmaceuticals (NASDAQ:CNSP) announced that its abstract has been accepted for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024), taking place November 21-24, 2024 in Houston, TX. The presentation, titled 'Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)', will be presented by Chief Medical Officer Sandra Silberman, MD, PhD, on November 22, 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2024 financial results, highlighting progress in its clinical development programs. The company completed enrollment of 252 patients in its pivotal Berubicin GBM study, with primary analysis data expected in H1 2025. Net loss increased to $5.6 million from $4.5 million year-over-year. R&D expenses rose to $4.2 million from $3.4 million. The company strengthened its cash position to $7.0 million, supplemented by post-quarter fundraising of $4.6 million, extending operations through Q2 2025. Additionally, CNS expanded its pipeline by in-licensing TPI 287, a late-stage brain malignancy treatment.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, Chairman of the Department of Neurology at the University Hospital in Zurich and National Coordinating Investigator for CNS's Berubicin study. The segment focused on glioblastoma multiforme (GBM), discussing unmet medical needs, current treatments, and Berubicin's potential as a solution for this condition.
CNS Pharmaceuticals (NASDAQ:CNSP) has received an extension from the Nasdaq Hearings Panel until March 11, 2025, to meet the minimum bid price requirement under Listing Rule 5550(a)(2). The company, which develops treatments for primary and metastatic brain and central nervous system cancers, now has additional time to regain compliance with Nasdaq's listing requirements.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a registered direct offering of 17,647,060 shares of common stock priced at-the-market at $0.17 per share. The offering, expected to close around October 24, 2024, aims to raise approximately $3 million in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced its participation in a Virtual Investor KOL Connect segment. The event featured key members of the CNS management team, including:
- John Climaco, Chief Executive Officer
- Dr. Sandra Silberman, Chief Medical Officer
- Dr. Don Picker, Chief Scientific Officer
Additionally, Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader, joined the segment. Dr. Goldlust currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and was previously an investigator in CNS's global potentially pivotal study of Berubicin.
The segment covered a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM), and explored the opportunities for CNS Pharmaceuticals in this field.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
